Physician profile
Mia Collucci
NPI 1841929411
$8,250.93
in general payments reported to CMS, 2019-2025
32 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,550 · 2023: $2,429 · 2024: $3,242 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,512 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,511.59 |
| Education | $189.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,745.89 | 2022-2025 | |
| Amgen INC. | $1,125.09 | 2023-2025 | Otezla, Enbrel, Evenity |
| Janssen Biotech, INC. | $939.84 | 2023-2025 | Tremfya, Simponi Aria |
| Ani Pharmaceuticals, INC. | $649.22 | 2022-2024 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $648.48 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $450.49 | 2023-2025 | |
| Pfizer INC. | $395.16 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $334.70 | 2022-2024 | Acthar |
| Horizon Therapeutics Plc | $291.49 | 2022-2023 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $214.66 | 2022-2024 | Quviviq |
| Pacira Pharmaceuticals Incorporated | $168.11 | 2023-2024 | Zilretta, Iovera |
| Lilly USA, LLC | $165.29 | 2022-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $148.83 | 2022-2024 | Lupkynis |
| Organon LLC | $144.04 | 2023-2025 | Hadlima, Renflexis |
| Janssen Scientific Affairs, LLC | $124.04 | 2024 | Simponi Aria, Tremfya |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $102.04 | 2022-2025 | Orencia |
| Genzyme Corporation | $76.14 | 2023-2024 | |
| Ucb, INC. | $69.46 | 2023-2024 | Cimzia, Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.63 | 2023 | Ofev, Cyltezo |
| Kowa Pharmaceuticals America, INC. | $55.63 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.56 | 2023 | Relistor |
| Phathom Pharmaceuticals, INC. | $43.78 | 2024-2025 | Voquezna |
| Hikma Pharmaceuticals USA | $42.12 | 2022-2023 | Mitigare |
| Collegium Pharmaceutical, INC. | $40.78 | 2022-2023 | Belbuca |
| Bayer Healthcare Pharmaceuticals INC. | $36.65 | 2022-2023 | |
| Sobi, INC | $28.95 | 2022-2023 | |
| Radius Health, INC. | $21.81 | 2024 | Tymlos |
| Glaxosmithkline, LLC. | $17.89 | 2025 | Benlysta |
| Alexion Pharmaceuticals, INC. | $17.00 | 2023 | Strensiq |
| Fresenius Kabi USA, LLC | $16.88 | 2023 | Idacio |
| Kiniksa Pharmaceuticals, LTD. | $14.69 | 2022 | |
| Sandoz INC. | $13.59 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mia Collucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.